Login / Signup

A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes.

Grit AndersenRosy EloySusanne FamullaTim HeiseGrégory MeiffrenCyril SeroussiMartin GaudierClaire MégretYou-Ping ChanOlivier SoulaMatthew C Riddle
Published in: Diabetes, obesity & metabolism (2023)
In comparison with aspart, ADO09 was well tolerated and effective in T1D across a wide range of dosage, significantly improving the average blood glucose level and body weight during 24 days of ambulatory treatment. Meal test profiles confirmed improvement of glycaemic patterns and other responses with ADO09.
Keyphrases
  • body weight
  • blood glucose
  • glycemic control
  • type diabetes
  • blood pressure
  • weight loss
  • insulin resistance
  • drug delivery
  • metabolic syndrome
  • replacement therapy
  • combination therapy